Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.

Details

Serval ID
serval:BIB_D1EFE02E95FD
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.
Journal
Current Gene Therapy
Author(s)
Coukos G., Courreges M.C., Benencia F.
ISSN
1566-5232 (Print)
ISSN-L
1566-5232
Publication state
Published
Issued date
2003
Volume
3
Number
2
Pages
113-125
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; ReviewPublication Status: ppublish
Abstract
The biological therapy of tumors using live viruses was first proposed a century ago but was abandoned due to potential virulence of wild-type strains. Thanks to advances in recombinant technology, replication-restricted strains have been genetically engineered, which replicate selectively within tumor cells. Examples include replication-competent mutants of herpes simplex virus (HSV), adenovirus, vesicular stomatitis virus, reovirus and measles virus. Replication-restricted oncolytic viruses are able to propagate selectively within solid tumor nodules exerting direct antitumor activity by killing infected tumor cells at the completion of a replicative cycle. In the process, they generate an intratumoral inflammatory response, which under the appropriate circumstances, may trigger the activation of an adaptive antitumor immune response, a process that has been named in situ tumor vaccination. Recombinant HSV may offer distinct advantages in oncolytic therapy of epithelial tumors. HSV is highly infectious to tumors of epithelial origin, resulting in high efficacy, there is considerable redundancy in HSV receptors, which makes the loss of HSV receptors by tumors due to mutations less likely and potent anti-herpetic drugs are commercially available, which may be used clinically to control undesired side effects. Herewith we describe the use of oncolytic viral therapy against intraperitoneal malignancies with special emphasis on oncolytic herpes simplex virus. We review the preclinical evidence on the efficacy and safety of intraperitoneal applications of HSV and discuss the rationale for its use for oncolytic therapy and in situ tumor vaccination of intraperitoneal tumors.
Keywords
Animals, Cancer Vaccines, Cytokines/metabolism, Dendritic Cells/virology, Genetic Therapy/methods, Humans, Inflammation, Mice, Mutation, Neoplasms/therapy, Neoplasms, Glandular and Epithelial/therapy, Peritoneal Neoplasms/therapy, Simplexvirus/genetics
Pubmed
Web of science
Create date
14/10/2014 11:43
Last modification date
20/08/2019 15:52
Usage data